Published in
Impact Journals, Oncotarget, 60(10), p. 6526-6535, 2019
DOI: 10.18632/oncotarget.27251
Links
Tools
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study
Journal article published in 2019 by
Sarina A. Piha-Paul 
,
Matthew H. Taylor,
Daniel Spitz,
Lee Schwartzberg,
J. Thaddeus Beck,
Todd M. Bauer ,
Funda Meric-Bernstam,
Das Purkayastha,
Linda Karpiak,
Sebastian Szpakowski,
Fadi Braiteh
,
Matthew H. Taylor,
Daniel Spitz,
Lee Schwartzberg,
J. Thaddeus Beck,
Todd M. Bauer ,
Funda Meric-Bernstam,
Das Purkayastha,
Linda Karpiak,
Sebastian Szpakowski,
Fadi Braiteh
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 